Mammary epithelial cells from midpregnant mouse have been used as a model to show that extracellular matrix (ECM) and some of its components (laminin, and heparan sulfate proteoglycan) play a fundamental role in regulation of milk protein synthesis and secretion. Using mouse and human c-DNA clones as well as polyclonal and monoclonal antibodies to the casein gene family (a, # and y), transferrin, whey acidic protein and a-lactalbumin, we have shown that the ECM regulates milk proteins at multiple points: (a) mRNA level; (b) protein synthesis and accumulation; (c) secretory rate and route; (d) the level and the nature of proteolytic activities, (3) hormonal inducibility and (4) lumen formation and vectorial secretion. Thus, a complex interplay between hormones, ECM and 'shape' determine whether or not a given protein is synthesized and how it is secreted. The results are consistent with a model of 'dynamic reciprocity' where ECM is proposed to influence gene expression via transmembrane proteins attached to cytoskeleton-in turn with connections to the nuclear matrix. A disruption of this interaction at any regulatory point will lead to destabilization of the differentiated state and may be a promotional event in cancer induction. Intestinal organogenesis and differentiation are driven by interactions between the endoderm and the mesenchyme. The developmental pattern of heterospecific or heterotopic recombinants between epithelial-mesenchymal anlagen allowed us to elucidate the respective role of both tissue components in morphogenesis, epithelial differentiation and hormone-elicited *Enquiries to the BACR Secretariat, c/o Institute of Biology, 20 Queensberry Place, London SW72DZ, UK. tReprints of these abstracts are not available -Ed.
Intestinal organogenesis and differentiation are driven by interactions between the endoderm and the mesenchyme. The developmental pattern of heterospecific or heterotopic recombinants between epithelial-mesenchymal anlagen allowed us to elucidate the respective role of both tissue components in morphogenesis, epithelial differentiation and hormone-elicited *Enquiries to the BACR Secretariat, c/o Institute of Biology, 20 Queensberry Place, London SW72DZ, UK. tReprints of these abstracts are not available -Ed.
responses. The endoderm is induced by the mesenchyme to differentiate into the polarized epithelial cell types characteristic of the intestine. Intramucosal fibroblasts of the differentiated intestine retain properties similar to embryonic mesenchyme. Among the mechanisms of tissue interactions, the possible mediation of information via the extracellular matrix is postulated. Positive arguments are brought about by the observation of compositional changes in matrix molecules during intestinal development and differentiation. Immunocytochemistry shows that basement membrane (BM) components are present at the epithelial-mesenchymal interface early in embryonic development and that changes in the spatial distribution of some extracellular matrix proteins within the mesenchyme are associated with morphogenetic processes. Cocultured or transplanted intestinal epithelialmesenchymal cell associations allowed us to show (1) that cell contacts between both cell populations are essential for deposition of BM components in a polar fashion at their interface; (2) the major role of the mesenchyme in the deposition of type IV collagen in BM and in remodelling of the glycosaminoglycans (GAG), mainly of hyaluronic chains.
The question whether epithelial cells in tumours synthesize different rates of ECM molecules or induce the adjacent mesenchymal cells to modify their synthetic pattern has been tested. Using human HT29 colon carcinoma cells, we could show that the shift from undifferentiated (sugar-containing medium) to differentiated cells (sugar-free medium) was accompanied by (1) an enhancement in the overall GAG synthesis; (2) the appearance of a new class of chondroitin, Cs4 sulfate; (3) a modification in the charge density of the heparan sulfate molecule. No major modifications in the synthetic properties of the mesenchymal cell compartment were obvious when HT29 cells were cocultured with skin fibroblasts.
Taken together, the different experiments stress the importance of the mesenchymal compartment in tissue interactions which take place in intestinal development and differentiation. The search for perturbations of the epithelialmesenchymal interactions in cancer is currently under study.
resolution to histology, in that the use of certain monoclonals in immunohistochemistry will sometimes reveal subpopulations of physiologically distinct cells within what appears to be a homogeneous tissue by conventional histological staining. Recent observations show that this is particularly true of epithelial tissues. We are currently applying monoclonal antibodies which are specific for single keratin intermediate filament proteins, as they become available, to an analysis of keratin expression in situ in the study of epithelial differentiation. Expression of any pair or pairs of type I +type II keratins, of the 30 or so keratins described in human tissues, is characteristic of a particular state (or states) of differentiation, and intermediate filament expression appears to be one of the earlier decisions made after induction of differentiation during the course of developmental organogenesis. In complex stratified epithelia we have observed that keratin expression also changes during the course of regeneration after wounding, and that keratin expression in tumours frequently resembles that of woundhealing situations. The data suggest that the intermediate filament phenotype is fundamental to tissue function, perhaps because of a dominant effect on tissue structure. The major question regarding intermediate filaments is still that of the evolutionary pressure which could drive the establishment of such extensive heterogeneity within this gene family: How do these filaments work? To look for functional differences between keratins and to investigate how tissue specificity might be effected, we are using bacterially-produced recombinant keratin fragments to investigate keratin subdomains, using mapped monoclonal antibodies as probes for defined regions of the keratin molecules. Vinculin and alpha-actinin are cytoskeletal proteins found in a family of specialised cell-cell and cell-substrate contacts called adherens junctions where they serve (along with a number of other components) to link microfilamentous actin to the membrane. Much of the interest in these structures stems from the observation that the interactions between the various cytoskeletal proteins is disrupted following tumourvirus transformation or exposure of cells to tumour promoters or growth factors. A detailed understanding of the mechanisms underlying these events has been limited by a lack of information on the structure of the cytoskeletal proteins involved. We have now determined the sequence of chick alpha-actinin (Baron et al., J. Biol. Chem., 262, 17623, 1987) and vinculin (Price et al., Biochem. J., 245, 595, 1987) and have begun to identify the functional domains in these two proteins. Thus residues 1-240 of alpha-actinin contain the actin binding domain; contains four 120 residue repeats which show homology to those in the cytoskeletal protein spectrin; the C-terminus of the protein contains two EF-hand calcium binding sites. Interestingly, the Duchenne muscular dystrophy protein contains a homologous actinbinding domain and spectrin-like repeats. Analysis of the deduced vinculin sequence shows that residues 259-589 consist of three 112 amino acid repeats contained within the globular head region of the molecule which is released by V8 proteinase as a 90 kDa-fragment. This fragment contains the N-terminus of vinculin and the talin-binding domain. The V8 cleavage site (Leu 858 ) is contained within a proline-rich region which separates the vinculin head from the extended tail. There is a candidate tyrosine phosphorylation site (Tyr 822) at the head/tail junction. Echinomycin and other members of the quinoxaline group of antibiotics bind to DNA by a mechanism of bifunctional (bis-) intercalation. Footprinting experiments have revealed that they associate preferentially with sequences in natural DNA containing the dinucleotide step CpG, though this requirement cannot be mandatory because binding also occurs to poly dG.poly dC and to poly (dA-dT). The molecular basis of sequence recognition is indicated by X-ray crystallographic studies. Features of the antibiotics which are critical for recognising the preferred base-pair sequences include peptide N-methylation as well as the CO and NH functionalities of the L-alanine residues in the octapeptide ring. Sequences flanking the antibiotic binding sites are subject to conformational changes which can be seen in footprinting patterns and by enhanced reactivity to chemical reagents; they may involve Hoogsteen base pairing.
Addition of echinomycin to reconstituted nucleosome core particles containing labelled DNA produces striking changes in the nuclease digestion pattern. Strong bands, representing new nuclease-sensitive sites, appear which cannot be attributed to simple displacement of DNA from the protein core. Fourier analysis of the perturbed digestion pattern suggests that antibiotic binding causes a shift in the positioning of DNA with respect to the histone octamer, equivalent to rotation of the entire polynucleotide by about half a turn. This change in rotational orientation occurs with eukaryotic as well as prokaryotic DNA fragments and can be seen after binding of other, non-intercalating, antibiotics such as netropsin and distamycin.
Oligonucleotides can be used to block mRNA translation. Covalent attachment of intercalating agents to oligodeoxynucleotides provides an additional binding energy which strongly enhances hybrid formation with complementary sequences. In addition oligonucleotide-intercalator conjugates exhibit an increased penetration across cell membranes and are protected against exonucleases. These modified oligodeoxynucleotides can be used to block gene expression both in vitro and in vivo. Their effect on protein synthesis is -at least in part -mediated by an RNaseH-induced degradation of mRNA in the oligodeoxynucleotide-mRNA hybrid.
The nuclease resistance of oligodeoxynucleotides can be markedly improved by using as building blocks synthetic [a]-anomers of nucleosides instead of the natural [f]-anomers.
Oligo-[a]-deoxynucleotides form double helices with complementary DNA sequences in which the two strands adopt a parallel orientation.
[a]-and [,B]-oligodeoxynucleotides can be covalently attached to reactive groups which can be activated either chemically or photochemically to generate irreversible reactions in their target sequence.
The major groove of the DNA double helix can be selectively recognized by oligopyrimidines which form a local triple helix at homopurine-homopyrimidine sequences. The oligopyrimidine is oriented parallel to the purine-containing strand. Irreversible reactions can be achieved on the native DNA double helix. This opens the way for selective regulation of gene expression at the transcriptional level. Our laboratory has studied the use of antisense oligonucleoside methylphosphonates (OMPs) to control gene expression at the mRNA level in living cells. These analogs contain nuclease resistant, methylphosphonate internucleoside bonds; form stable, hydrogen-bonded complexes with complementary sequences of single-stranded RNA and DNA; and are taken up intact by mammalian cells in culture. OMPs targeted against initiation codon regions of vesicular stomatitis virus mRNAs or against the acceptor splice junction regions of two Herpes simplex type 1 precursor mRNAs specifically inhibit virus function in virus-infected cells in a sequence dependent manner. We have also prepared OMPs derivatized with 4'-N(2-aminoalkyl)-aminomethyl-4,5', 8-trimethylpsoralen, photoactivatable crosslinking groups.
These oligomers specifically crosslink with targeted mRNA upon irradiation at 365nm and specifically inhibit mRNA translation in cell free systems at low (1-5 MM) concentrations. A psoralen-derivatized oligomer complementary to the initiation codon region of VSV N-protein mRNA inhibits VSV protein synthesis at 5 uM concentration when VSVinfected cells are irradiated in the presence of the oligomer. Because OMPs are very stable in media containing mammalian serum and are readily taken up by mammalian cells, they should be quite useful as antisense agents in cell culture experiments and possibly in experiments involving animals. It appears that psoralen-derivatized OMPS may be particularly effective as inhibitors and that they could be used to help define the cellular target(s) of the oligomers and thus the mechanism of action of the oligomers in cell culture systems.
Synthesis and evaluation of N-ras anti-sense and nonsense methylphosphonate oligonucleotide analogues D. Tiddl, P. Hawley2 & I. Gibson2 'Department of Radiation Oncology, Clatterbridge Hospital, Wirral, Merseyside and 2School of Biological Sciences, University of East Anglia, Norwich NR47TJ, UK.
Anti-sense 8-mer nonionic methylphosphonate oligonucleotide analogues have been reported to inhibit target gene expression in intact cells by virtue of their ability to (i) cross cell membranes, (ii) resist nuclease degradation, and (iii) form sequence specific hybrids with mRNA (Miller & Ts'o, Anti-Cancer Drug Design, 2, 117, 1987) . We are interested in using this approach as a means of investigating the relation between oncogene expression and maintenance of the transformed phenotype. A methylphosphonate 9-mer anti-sense to codons 1-3 of the human N-ras gene and a 'nonsense' scramble of this sequence were synthesized by both the phosphotriester analogous and the new methylphosphonamidite chemistries. The two oligonucleotide analogues were shown by MIT assay to be completely non-toxic to human HT29 cells in culture at concentrations of up to 80 uM, and in addition, we confirmed by HPLC analysis that no detectable degradation of the molecules occurred in cultures over 48 h. A phosphodiester oligodeoxynucleotide 20-mer corresponding in sequence to codons 1-7 of the human N-ras gene was used to investigate the hybridization properties of the methylphosphonates in solution. At low temperature (<5°C) both anti-sense and nonsense analogues formed 1:1 complexes with the 20-mer probe, but these were largely dissociated at 25°C. Only a fraction (10-20%) of the molecules in the anti-sense preparations formed stable hybrids with the 20-mer. This could conceivably mean that most of the 256 diastereoisomeric forms present in the purified 9-mer were unable to form Watson-Crick base pairing interactions along their entire length. The melting temperature of the hybrids which did form was approximately 34°C. Our preliminary cell culture results were not repeated in subsequent experiments, which showed no effect of the anti-sense oligonucleotide on induction of p2lN-raS protein synthesis by dexamethasone in T15 cells, a line of NIH3T3 cells transfected with multiple copies of the human N-ras gene under control of the MMTV promoter.
Pyrrolo (1, 4) Anthramycin and tomaymycin are members of the pyrrolo-(1,4)benzodiazepine antibiotic group. These drugs bind covalently in the minor groove of DNA through N2 of guanine. Previous studies have shown that PuGPu sequences are the most favoured for binding, while PyGPy sequences are least favoured. Using a combination of fluorescence, 1H and 31p_ NMR, and molecular modelling studies we have examined the binding of tomaymycin and anthramycin to -various oligomers including d(ATGCAT)2. While anthramycin only forms one type of adduct with the duplex, tomaymycin forms two adducts in approximately equal amounts. Anthramycin binds via a 11S linkage geometry with the aromatic ring to the 3' side of the covalently modified guanine, while tomaymycin binds with either an 11S or 11R linkage geometry. Molecular modelling and 1H-NMR studies suggest that the IlS isomer binds in the 3' orientation while the IIR isomer binds in the 5' orientation. Upon binding of anthramycin to DNA the covalently modified strand undergoes a selective conformational change up to three bases to the 3' side of the adduct. At the covalent linkage site the glycosidic dihydral angle is dramatically changed and the pucker of the sugar to the 3' side assumes the unusual C4'-endo conformation. The sugar-phosphate backbone torsion angles between the covalently modified guanine and the two bases to the 3' side also appear to have undergone changes resulting in significant changes in the base to H ' and H2' and H2" distances and Interactions at the primary site of tumour growth could be very important in affecting metastasis. Recent studies (Karre et al., Br. J. Cancer., 36, 503, 1985) have suggested that interferon-stimulated MHC expression may be linked to increased metastasis via reduced NK cell recognition. In the current study we provide further support for this proposal, and present evidence to suggest that this mechanism could be operating in vivo and explain the observed variation in metastasis with primary implantation site. Class I molecules (KbDb) were not detected on the surface of cultured murine melanoma cells (B16-BL6) using cell surface radiolabelling, immunoprecipitation and electrophoresis. This finding was further confirmed by screening mRNA isolated from BL6 cells with synthetic oligonucleotide probes to class I sequences. However, class I molecules were detected if the cells were grown s.c. and then reintroduced into culture. In other experiments, treatment of MHC-negative cells with IFN-y (10-10,000 Uml-') induced class I expression (as measured by immunoprecipitation), and the acquisition of sensitivity to anti-Kb-specific cytotoxic T cells) but 54, 271, 1975 TPA potently inhibits the growth of A549 human lung carcinoma cells with an IC50 of 0.1 nM (Gescher & Reed, Cancer Res., 45, 4315, 1985) . Mezerein, a tumour promoter which is structurally related to TPA, induces less potently the same growth-inhibitory effects as TPA (IC50 4 nM) (Dale & Gescher, Br. J. Cancer., 56, 184, 1986) . In the present study the potential role of PKC in the TPA-induced growth arrest of A549 cells has been further investigated. It was found that the synthetic diacylglycerols l-oleoyl-2-acetylglycerol and 1,2-dioctanoylglycerol were unable to induce growth arrest at non-toxic concentrations (< 100 yM).
Also, the specific PKC inhibitor H-7 at concentrations of up to 100 pM did not alter growth inhibition induced by 10 Table) , SuSa-CP was 6-fold more resistant than SuSa, and RT112-CP was 4-fold more resistant than RT112. These levels of resistance were retained when the sublines were maintained in the absence of CP for 3 months.
The isozyme profiles, population doubling times (PDT) and plating efficiencies (PE) of parent and resistant cell lines were studied (see Table) . The isozyme studies showed that the resistant sublines were not cross-contaminated with other cell lines. After 5 to 7 days proliferating cells were subcultured onto fibroblast feeder layers and were treated in situ with doxorubicin at a range of concentrations for 24h. Colonies were then counted after two weeks. The drug concentration required to kill 50% of the tumour cells varied about twenty-fold (range 2.7 x 10-8 to 6 x 10-7 M). In all eleven patients, the dose response curves were similar for tumour and for normal breast.
These findings suggest that there is marked inter-patient variation in doxorubicin sensitivity, but that breast tumour sensitivity is close to that of normal tissue in a single individual. The growth inhibitory effects of recombinant interferons (IFNs) x and y on human lung cancer cell lines was studied using both a tetrazolium (MTT) colorimetric assay and direct cell counting. Significant discrepancies between the two assays were observed (see table below). HMBA (1.0mM) reduced the DDC activity in both NCI-H187 (P<0.05) and NCI-H69 (P<0.01), and increased the CKBB activity in H69 (P<0.05). Moreover, sodium butyrate (0.1 mM) reduced the DDC levels in the three lines examined, H187 (P<0.01), H69 (P<0.001) and NCI-HI28d (P<0.02), and increased the CKBB levels in H187 (P<0.01) and H69 (P<0.05). Similarly, dibutyryl cAMP (0.5 mM) was also found to reduce the DDC activity in H69 (P<0.05), and increase the CKBB levels (P<0.05). All drug concentrations used were non-cytotoxic.
These results suggest that the SCLC phenotype can be altered by drug treatment. We have investigated whether these phenotypic changes affect the chemosensitivity of the cells. A chemosensitivity assay was used based on the reduction of a tetrazolium dye. The adriamycin ID50 was found to be 3.51 X 10-8 M for H187, 4.37 x10-8 M for H69 and 7.5 x 10 -8 M for H128d. However, the effect of the above drug induced changes on the chemosensitivity of the cell lines is as yet unclear.
Actions of a progestogen on the efficacy of cytotoxic drugs Rep., 9, 219, 1985) an assay for Chinese hamster ovary cell viability that is based on the ability to multinucleate in the presence of the fungal metabolite cytochalasin B (CB) following exposure to radiation or to cytotoxic drugs. The degree of multinucleation achieved is assessed after a given incubation period in CB by measurement of the cellular DNA content using the flow cytometer. The method is intended to permit estimation of the survival of DNA synthesis in situations where cells cannot be fully monodispersed.
Cells were seeded from the same stock culture at either 400 cell/flask for conventional clonogenicity studies, or at 1 x 10E6 cell/flask for the estimation of the DNA content following incubation in CB. All cultures were exposed to the same cytotoxic drug solution, or to 137-Cs gamma irradiation either at a high dose-rate of 0.5 Gy min 1, or at a low dose-rate of about 1 cGy min-1.
Radiation survival curves after single doses up to 20 Gy are exponential, with no evidence for a threshold in the survival of the ability to reach a DNA content of at least 3 x GI in the presence of CB. We have investigated the relationship between this apparent lack of repair of sublethal damage in the multinucleation system to the change in survival curve slope at low dose rates. Comparisons have also been made between the survival of clonogenic potential and the survival of DNA synthesis, in CHO cells exposed to cisplatinum, Novantrone, cytosine arabinoside, 5-fluorouracil, or vinblastine, all as single agents. The membranes of malignant cells showed increased oleic acid in relation to stearic acid content in comparison with their normal counterparts (Wood et al., Eur. J. Onc., 11, 347, 1985) . The cytotoxic effects of saturated stearic, monounsaturated oleic and dihydroxystearic acids on two testicular tumour (SuSa, 833K), two bladder carcinoma (RT112, RT4), one colorectal tumour (HT29), one normal urothelium (HU609) and one normal fibroblast (HFL) cell lines were measured using a colony forming assay. Stearic acid was up to five times more cytotoxic than oleic acid. All tumour cell lines with the exception of RT4 were more sensitive to stearic acid than the normal fibroblasts ( < 0.001 < P < 0.05). However the well differentiated bladder tumour, RT4 was more sensitive than normal fibroblasts to oleic acids (P<0.05). It was also found that the 3 tumour cell lines tested were more sensitive than the normal urothelium and fibroblasts to dihydroxystearic acid (data not shown). Our data suggest that the stearic acid is more cytotoxic to tumour cells than oleic acid, and that this may be related to the higher proportion of oleic acid in the tumour cell membranes. The aim of this work was to study the effect of temperature on the cytotoxic effect of melphalan using human melanoma MTS.
We have grown MTS from several established cell lines. MTS of the B8 line were exposed to clinically achieved concentrations of melphalan for 1 h at temperatures from 31 to 44.5°C. Spheroid volume was measured subsequently to obtain growth curves. Spheroids were also disaggregated for clonogenic assay.
Using regrowth delay and clonogenicity of disaggregated spheroids our results show that, despite the increased rate of hydrolysis of melphalan at higher temperatures, the cytotoxic effect of the drug is enhanced by heat. At hypothermic temperatures there was no significant difference in cytotoxic effect compared with normothermia.
These results support the use of hyperthermia during ILP with melphalan. Testicular germ cell tumours are curable in advanced stages using chemotherapy, unlike most other types of cancer. Drug resistance in all forms of cancer may develop as a result of mutation induced by chemotherapy. The spontaneous and induced mutation frequencies (MF) in cell lines derived from three testicular (SuSa, 833K, GH) and two bladder (RTl 12, RT4) tumours were compared. In addition MF were compared also in a testicular and bladder subline made resistant to the drug cisplatin (SuSa-CP, RTl 12-CP). Hypoxanthine guanine phosphoribosyl transferase (HGPRT) locus mutations were selected by resistance to 10 jug ml-6 thioguanine. Induced mutation frequencies were compared following exposure to a range of concentrations of the mutagen ethyl methane sulphonate (EMS) (see Table) . Within the bladder and testicular cell lines there is overlap of both spontaneous and induced MF. In the cell lines made resistant to cisplatin there is no significant change in MF. In these cell lines there is no association between drug sensitivity or resistance and mutation frequencies.
Elevation of H{L-60 cell intracellular calcium by the cytotoxic ether Upid SRI 62-834 and antagonism by 12-0-tetradecanoyl-phorbol-13-acetate vented by the protein kinase C-activating phorbol ester, 12-0-tetra -decanoyl -phorbol -13 -acetate (TPA). After a 10 min preincubation with 3 nM TPA, the calcium rise induced by 30,uM SRI 62-834 was 50% inhibited, and lOOnM TPA completely abolished it. This suggests that the elevation of intracellular calcium mediated by SRI 62-834 is possibly the result of the opening of a calcium channel, the activity of which is regulated by protein kinase C.
In vivo-induced resistance to chloroethylating agents correlates with increased O(-alkylguanine DNA alkyltransferase expression in a murine solid tumour 
is a tetrahydrofuran analog of the antitumour ether lysophospholipid Et-18-OCH3(l -0 -octadecyl -2 -0 -methylrac -glycero -3 -phosphocholine). The cytotoxic and differentiation-promoting activity of the ether phospholipids, such as Et-18-OCH3, is considered to be mediated either via direct effects, and/or indirectly by the activation of cytotoxic macrophages. The direct cytotoxicity has been suggested to be the result of the inhibition of normal phospholipid metabolism and the subsequent perturbation of membrane function. In view of this, we have investigated the activity of SRI 62-834 on the calcium homeostasis of HL-60 human promyelocytic leukaemia cells, and find it rapidly to elevate intracellular calcium concentrations in a concentrationdependent manner, as monitored by the calcium indicator, Quin-2. In a typical experiment, 30 pM SRI 62-834 elevated the concentration of intracellular calcium from a resting level of 179 nM to 445 nM/1.5 x 10 cells. This was partially inhibited by preincubation with the voltage-dependent calcium-channel blocker, verapamil, and completely preChanges in cellular glutathione and glutathione-S-transferase levels associated with resistance to L-phenylalanine mustard (melphalan) Cellular glutathione plays an important role in the modulation of alkylating agent cytotoxicity. The relationship between cellular glutathione transferase (GSH-TFR), GSH and GSSG levels and alkylating agent resistance has been studied in the human ovarian OAW42 cell line. The effect of oxothiazolidine-4-carboxylate (OTZ) and buthionine sulfoximine (BSO) has also been determined. The melphalanresistant subline OAW42/MER was developed by step-wise incubation with the drug, and found to be 4-fold more resistant to melphalan than the parent OAW42 line. Total glutathione and GSH-TFR activity were 1.5 fold greater in OAW42/MER than in OAW42. The GSSG/GSH-TFR ratio was 0.1 1 in OAW42, and 0.25 in OAW42/MER. The difference in glutathione levels was therefore attributed to an elevation in GSSG content of OAW42/MER. 50 uM BSO (18 h) potentiated melphalan cytotoxicity by a factor of 2 in both cell lines, and reduced total glutathione to 78.6% and 40.3% of control values respectively in OAW42 and OAW42/MER. The level of GSSG was unchanged in OAW42 but fell to 8.6% in OAW42/MER. GSH-TFR activity decreased to 64% of control levels in both cell lines. The GSSG/GSH-TFR ratio remained at 0.11 in OAW42 cells, but fell to 0.08 in OAW42/MER.
Exposure to 50,uM OTZ for 18 h reduced melphalan cytotoxicity by 5-fold, and significantly increased the GSSG/ GSH-TFR ratio in OAW42 to 0.20. Total glutathione levels were not altered, but the GSSG/GSH ratio increased by 2 fold. These results suggest a correlation between the proportion of total glutathione in the oxidized form GSSG, GSH-TFR activity and the degree of resistance to melphalan. The glutathione-S-transferases (GSTs) are a multigene family of enzymes which play a role in many cellular detoxification reactions. Evidence is emerging that these enzymes also play a role in the development of resistance to cytotoxic drugs and anti-neoplastic agents. We are studying the relationship between GST expression in human tumour cell lines and their susceptibility to these compounds. The MCF7 cell line which contains essentially no GST was much more sensitive than the cell line HT29 to the toxic effects of GST substrates and chlorambucil. In an alternative approach we have made a human lung tumour cell line (NCI H322) resistant to the GST substrate CDNB. The resistant line demonstrates dramatic over expression of GST activity (24 fold), to levels higher than any normal human tissue, including the liver. Elevation in both the acidic and basic subunits accompanied this change. The basic subunit being elevated greater than 100 fold in the resistant line. The calcium antagonist verapamil has been shown to increase the sensitivity of a number of cell lines to cytotoxic drugs in vitro and it has been suggested that it may be of value in attempts to overcome drug resistance in patients.
Although verapamil (6.6pM) increased the sensitivity of a number of non-small-cell lung cancer (NSCLC) cell lines to adriamycin, this effect was not observed if verapamil was added to the cells subsequent to addition of adriamycin. This suggested that verapamil is not active if the cells have already been exposed to the cytotoxic drug. We have, therefore, determined the effects of pre-treatment of cells with verapamil prior to exposure to adriamycin.
Chemosensitivity was determined by an assay based on the reduction of a tetrazolium dye, MTT, by live but not dead cells. Cells were plated in 96 well plates and exposed to adriamycin for 24 h. For the NSCLC cell line WIL the ID50 for adriamycin alone was 3.0 x 108 M. This was reduced 5-fold by exposure to adriamycin for 24h in the presence of verapamil (6.6 gM). However, when cells were incubated for 24 h in the presence of verapamil (6.6 gM) prior to addition of adriamycin and verapamil, the ID50 was reduced by 20- fold. In contrast addition of verapamil for 24h after exposure to adriamycin and verapamil did not further reduce the sensitivity of the cell line. Furthermore, pre-incubation with verapamil for 24 h prior to exposure to adriamycin alone had no effect on the chemosensitivity. 56, 55, 1987) that the immunosuppressive agent cyclosporin A (CYA) is an effective modifier of resistance to adriamycin (ADM) and vincristine (VCR) in the multidrug resistant variant (LX4) of the human cell lung cancer cell line NCI-H69. Three naturally-occurring analogues of CYA were also examined and we found that their ability as resistance modifiers (RMs) correlated with their immunosuppressive properties.
We have now examined a further series of 6 non-or minimally-immunosuppressive analogues of CYA, either synthetic or derived from naturally-occurring compounds. Several of these have been found to be highly effective RMs. Furthermore, two compounds, B3-243 and W8-032 maintained good activity in the dose-range 1-2 ig ml-1 (sensitisation of LX4 cells to ADM at 2 ig ml-1 = 53 and 32 fold respectively), whereas sensitisation to ADM by CYA falls from 50 fold at 5 gml to 10 fold at 21ugml-1.
Preliminary experiments in mice have indicated that B3-243 can be administered in 5 daily doses of 100mgkg-1day-1 without acute toxicity. Such a schedule results in blood levels in the range 1-2 jugml-1, i.e. similar to those which produce effective resistance modification in vitro. Experiments combining B3-243 and ADM in mice bearing ADM sensitive and resistant tumours are in progress. Invasion of bone by tumours usually involves osteolysis as well as some osteogenesis. Multiple myeloma is unusual in that only osteolysis occurs in the vast majority. To examine the effect of myelomata on osteogenesis, the myeloma cell line GM 1500 was co-cultured with human bone-derived cells (BDC). The BDC were also cultured in medium conditioned by the myeloma cells (MCM). BDC proliferation was measured by cell count and DNA synthesis by tritiated thymidine uptake (3H-TdR) assay. Both cell proliferation and DNA synthesis were inhibited by MCM (by 31% and 41% respectively). Proliferation of BDC co-cultured with myeloma cells was also inhibited (26%). This inhibitory effect was dependent upon myeloma cell density in the conditioning medium. Preliminary work showed that this effect is dose dependent, and that the active component has a molecular weight of less than 50,000 daltons. The usual response of bone to injury (including tumour invasion) is osteogenesis. The results of this pilot study suggest that myeloma inhibits this reaction by the secretion of a soluble osteoblast inhibiting factor. The application of NMR spectroscopy to the study of living cells provides a valuable method for the non-invasive monitoring of cell energetics and ionic content.
We have used 31p NMR to study metabolic changes related to hypoxia in cultured HT29 human colon carcinoma cells in vitro and characterised the 3'PNMR spectrum in monitoring changes occurring during recovery from hypoxia. Phosphate metabolites were monitored with time as the environment in the NMR tube became increasingly hypoxic for the sedimented cell pellet. Considerable changes in the levels of these metabolites were observed. These changes are comparable with those observed in vivo tumour with disappearance of phosphocreatine and glycerophosphorylcholine and concomitant increase in inorganic phosphate and are almost completely reversed following reversal of hypoxia by resuspension and reoxygenation in fresh medium. This technique when used to compare cells irradiated by photons or neutrons to controls resulted in different patterns of recovery following irradiation which showed dose response effects. These investigations suggest a potential for NMR spectroscopy as an early in situ method of studying the response of tumours to radiotherapy. 10pm column with a running buffer of 45% methanol in 20mM sodium phosphate buffer, pH 7.4. E09 and internal standard, E012, were detected by absorption at 280nm.
The projected peak plasma levels were 422ngml-P and the drug was rapidly eliminated with a half-life of 4.2min. The volume of distribution was large at 355ml and the clearance 59 ml min-1. Urine from animals receiving E09 had a bright red appearance, though no parent drug was detected in urine. This pharmacokinetic profile differs greatly from the indoloquinone prototype, mitomycin C. When administered at the same dose, mitomycin C was eliminated with a half-life of 12 min, and exhibited a volume of distribution of 35 ml, clearance of 2 ml min-1 and peak plasma levels projected at 4.3ygml-1. These results show that active concentrations of E09 can be achieved in vivo, though it may be appropriate to modulate pharmacological behaviour by using alternative delivery methods or modified analogues.
Gene amplification as a mechanism of resistance to a novel folate-based thymidylate synthase inhibitor in human W1-L2 cells We reported previously a mutant L1210 cell line with acquired resistance (>200 fold) to the TS inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717). TS was overproduced 45-fold and this was shown to be due to amplification of the TS gene. A small (2,5-fold) increase in dihydrofolate reductase (DHFR) was also observed (Jackman et al., Cancer Res., 46, 2810 , 1986 ). This resistant cell line has therefore provided a useful source of murine TS. We report here six human lymphoblastoid cell lines (WI-L2: Cl-C6) with acquired resistance (>10,000 fold) to the 2-CH3 analogue of CB3717. This analogue is a 2-fold poorer TS inhibitor than CB3717, but is 40-fold more cytotoxic. It was hoped that these WI-L2 cells would overproduce TS in a manner similar to L1210 and thus be a source of human enzyme. Resistance was raised by subjecting the cells to incremental concentrations of the 2-CH3 analogue of CB3717 and then cloning them in microtitre plates. The resultant cloned cell lines (WI-L2: C1-C6) were found to have increased TS activity (200-fold) compared with the parent line. TS gene amplification was also demonstrated by the use of a TS cDNA probe. DHFR activity in the cloned cell lines was not elevated compared with the parent line, and the DHFR gene was not amplified. Only a 40% decrease in TS activity was found when the resistant cells were grown in the absence of the 2-CH3 analogue of CB3717 for >390 generations. The resistant line WI-L2:Cl was investigated further. This line showed cross-resistance to other folate-based TS inhibitors e.g., CB3717 and 2-desamino-CB3717 but was collaterally sensitive to the DHFR inhibitor methotrexate (MTX). The TS enzyme was partially purified from both the resistant and sensitive Wl-L2 cell lines and Kiapps for the 2-CH3 analogue of CB3717 were estimated to be 21.94+0.64 nM (Wl-L2:Cl) and 22.3 +0.516 nM (WI-L2). It therefore seems unlikely that resistance is due to the TS enzyme having a decreased affinity for the 2-CH3 analogue of CB3717. Moreover the Kiapps of a wide variety of folate-based TS inhibitors using TS from these resistant cells were similar to those obtained using TS from the mutant L1210 cells. Paterson BDF mice were treated with LD50 doses of cisplatin (15mgkg-1), iproplatin (45mgkg-1) and paraplatin (150 mgkg-1). Animals surviving the period of acute toxicity were treated at day 14 with the acute nephrotoxin uranyl nitrate (16 mgkg-1) which induces tubule necrosis. The ability of the renal epithelium to recover from this injury was assessed by sub-capsular tubule count and thymidine autoradiography. In control animals uranyl nitrate reduced the sub-capsular tubule count from 508 + 5 to 229 + 4 2 days after treatment. The sub-capsular count returned to control 7 days after treatment. Recovery was marked by an increase in cortical labelling indices from control levels of 0.21 +0.03% to 10.6 + 1.0% by day 3. Treatment 14 days previously with iproplatin or paraplatin did not influence the renal response to uranyl nitrate, however, prior treatment with cis-platin had a potent inhibitory effect. 7 days after treatment with uranyl nitrate the sub-capsular count was 208+8 compared to 490 + 23 in the uranyl nitrate only group and 338 + 6 in the cisplatin only group. The peak labelling index was 5.4 + 0.5% in the cis-platin and uranyl nitrate group.
Three months after cisplatin, there was still evidence of a reduced ability to recover from uranyl nitrate induced damage.
It is concluded that following LD50 doses cisplatin, unlike iproplatin and paraplatin, has a significant and long-term effect on the renal response to a secondary cytotoxic insult. When administered as a single i.v. injection human recombinant TNF produced a dose-related weight reduction that was accompanied by and directly proportional to a decrease in both food and water intake. When given as two separate injections over a 24 h period, hypoglycaemia, hypertriglyceridaemia and a decreased level of circulatory FFA were observed 60 to 90 min after the final injection. The degree of hypoglycaemia is proportional to both the weight loss and the decrease in food and water intake.
In order to investigate the mechanism of the weight loss produced by TNF, animals were dosed orally with either water alone or a concentrated glucose solution. Weight loss was reversed by oral administration of water; the increase in weight being accompanied by an increase in total body water. Administration of a concentrated glucose solution had no greater effect than water alone in reversing the weight loss, indicating that the observed hypoglycaemia is not important in this action of TNF. Weight loss produced by TNF was also reversed by the i.p. administration of indomethacin (10mgkg-) 2h prior to the TNF injection. These results suggest that weight loss produced by TNF appear to be the result of prostaglandin production and dehydration. Various methods are currently being used for monitoring human exposure to alkylating agents. We are in the process of developing an analytical technique for quantitating the extent of exposure to such compounds as nitrogen and sulphur mustard by determining the formation of amino acid adducts in skin and hair samples. In order to identify the specific sites of reaction of these compounds with proteins, preliminary in vitro studies were carried out using polyamino acids as substrates. Nitrogen mustard (HN2) was incubated with poly-L-histidine, poly-L-valine, poly-L-serine, poly-Ltyrosine, or poly-L-lysine in 0.1 M sodium phosphate buffer pH 7.4 at 37°C. The reactions were initiated by addition of 14C-labelled HN2 (106 dpm, sp.a. 22 mCi mmol-1) to the incubation mixtures and stopped with ice-cold ethanol. The polyamino acids were precipitated on glass fibre filters and the bound radioactivity was counted. The rates of reaction were similar for all polyamino acids: the maximum degree of binding was reached between 3 and 4h from the beginning of the experiment and remained constant up to 6 h. The most reactive substrate was shown to be poly-L-valine with 3% of the initial radioactivity bound after 1 h, followed by poly-L-serine and poly-L-histidine (2 and 1.8%, respectively). Although these data do not necessarily reflect an in vivo situation, they may provide some information on potential target amino acids for NH2 and the relevant adducts for future analytical work. Molecular orbital calculations for N-(hydroxymethyl)amides, including the anti-tumour N-(hydroxymethyl)formamide, have established that the half-lifes (t,1/2) of these hydroxymethylamides at pH 7.4 and 37°C may be reliably estimated from the N-CH20H bond length, calculated using the MNDO method. Longer bonds are indicative of more reactive compounds and, as shown in the table below, this relationship is approximately maintained when extended to N-(hydroxymethyl)pentamethylmelamine (the active metabolite from hexamethylmelamine), trimelamol and 1-aryl-3-(hydroxymethyl)-3-methyltriazenes (e.g. the N-hydroxymethyl derivative of DTIC). Since the anti-tumour activity of these compounds is related to their half-lifes it should now be possible to assess the anti-tumour activity of analogues by molecular orbital calculations prior to synthesis. For the development of targetted drug conjugates, it would be useful to account for the specific cytotoxicity of these compounds by the quantitation of their intracellular delivery. Assuming from the kinetics of uptake of antibody (see accompanying paper) and fluorescent conjugates that this is by pinocytosis, several possibilities for endocytosis exist.
Either specific or non-specific adsorptive (predominant at low conjugate concentrations), and non-specific fluid phase (predominant at high conjugate concentrations).
The non-specific component has been measured by uptake of radiolabelled components into cells and expressed as an endocytic index (Ml uptake of medium 10-6 cells h-1), and the specific uptake of 1251-791T/36 antibody and 1251-791T/ 36-HSA-MTX conjugates have been determined using the quantitative radiolabelling method described in the accompanying paper. These results showed that uptake of HSA (used as a fluid phase marker) was at an average of 1.9 jul medium 10-6 cellsh-1, but that HSA-MTX was apparently taken up at 5.7 pl medium 106 cells h-1. The use of varying quantities of labelled material diluted with varying amounts of unlabelled material demonstrated a small but significant amount of membrane bound HSA-MTX. These data together with rates of antibody and conjugate endocytosis can be used to assess relative specific and non-specific endocytic uptake of drug-antibody conjugates. As part of a study to investigate the possibility of using antibodies to target BrdU for radiosensitisation, the colonic adenocarcinoma cell line (HT29/5) and a chinese hamster lung line (V79a) were exposed to 0, 3, 30 and 300 imol BrdU for periods of time ranging from 30 min to 7 days. Relative BrdU incorporation was measured by a two stage fluorescence technique using a BrdU specific monoclonal antibody and flow cytometry. The biological effect of BrdU was measured using clonogenic and 3(4,5-dimethylthiazol-2-yl)-5-diphenyl tetrazolium bromide (MTT) assays. Following optimisation for each cell line of MTT test conditions, there was good correlation with the clonogenic assay in cell survival curves. There was also a correlation between cell survival and amount of BrdU incorporated. BrdU incorporation was shown in cells incubated with BrdU-polylysine conjugates thus allowing the potential feasibility of BrdUpolylysine-monoclonal antibody conjugates as vehicles for selective localisation of BrdU. The use of this technique is now being extended to confirm uptake of non-ionic oligonucleotide probes into whole cells by the use of BrdU within the nucleotide sequences. The blood kinetics and tumour localisation of conjugates of methotrexate (MTX) and daunomycin (DAU) and the monoclonal antibody 791T/36 have been examined in nude mice with human tumour xenografts. The antibody moiety of the conjugates were followed by labelling with 125-I and the drug moieties using radioimmunoassays.
After radioiodination, the drug moieties were coprecipitable with the radiolabel using TCA or rabbit antimouse IgG antiserum. Following i.v. injection, serum kinetics of both the antibody and drug moieties of both of the conjugates were essentially similar, and the integrity of serum-borne conjugate was confirmed by the co-precipitation of radiolabel and drug. The radiolabelled antibody moiety of the conjugate localised in tumour xenografts and the levels were maintained for up to 4 days. The declining serum levels and relatively constant tumour levels of radiolabel resulted in a progressive increase in tumour to serum ratios. Analysis of tumour levels of the drug moiety showed a similar pattern, with up to 4% of the injected dose being present per gram of tumour over the 4 day observation period with progressively increasing tumour to serum ratios of the drug, the ratios being virtually identical to those with antibody. Parallel studies with free drugs showed rapid clearance from the blood and a maximum of 0.35% of the dose/g of tumour 30 min after injection. Control immunoglobulin conjugated to MTX did not show tumour localisation of either the antibody or drug moieties.
These studies confirm the in vivo stability of these types of drug antibody conjugates and demonstrate site-specific targetting of therapeutic agents. An immunotoxin constructed by conjugating ricin A chain to monoclonal antibody 791T/36 specifically suppresses growth of human tumour xenografts and is in clinical trial for the treatment of colorectal cancer. The objective of immunotoxin therapy is to target the cytotoxic moiety (ricinA chain) to tumour cells and this requires that the product localizes efficiently in tumours. In this respect ricin A chain -791T/36 antibody conjugates (RTA-791T/36) have a markedly altered biodistribution when compared to unconjugated antibody. This is principally manifest as hepatic uptake of immunotoxin which appears to be controlled by the ricin A chain (RTA) moiety. This was established by comparing the blood survival and organ distribution of immunotoxin with that of ricinA chain and free antibody using preparations in which either the RTA or antibody alone or as components of the immunotoxin were radiolabelled. Hepatic uptake is dependent upon Kupffer cell recognition of mannose-containing oligosaccharide structures on the RTA moiety of immunotoxin. Mannose-containing blocking agents given with immunotoxin were shown to prolong circulation time of the immunotoxin in blood and reduce liver uptake. Effective blocking agents include glycoproteins such as ovalbumin, ovomucoid and mannosecontaining compounds including mannosyl-lysine. These agents specifically inhibit hepatic uptake of immunotoxin so altering biodistribution. Immunotoxin administered together with blocking agents preferentially localises in human tumour xenografts compared with immunotoxins alone and this should improve therapeutic efficacy. When cultured in vitro human PBM fuse to form MGC which resemble foreign body giant cells and osteoclasts. This phenomenon has been shown to occur commonly in women with breast cancer (BC) but infrequently in unaffected controls (Al Sumidiae et al., Br. J. Surg., 73, 839, 1986) . The aim of this study was to determine whether MGC formation antedated the development of BC by culturing PBM from women at 50% lifetime risk by virtue of a strong family history (FH at least 2 affected first degree relatives). Ten ml peripheral venous blood was collected aseptically from 40 women with BC, 40 healthy control women with no FH of BC, and 20 first degree relatives of women with a strong FH of BC. PBM were separated over a Ficoll-Hypaque gradient. Without further purification 2 x 106 cells ml-1 were incubated in Iscove's modified Dulbecco's medium plus 15% foetal calf serum at 37°C in an atmosphere of 5% CO2/95% air. Medium was changed weekly. MGC (>3 nuclei/cell) began to appear after 7-10 days and cultures with >2MGC/ 590 1i2 were counted as positive. At 17 days the mean number of MGC in positive cultures was 24.2 + 5.0 (s.d. n=15) and was 43.1+7.3 at 24 days. MGC synthesised an osteoclast marker and tartrate resistant acid phosphatase. MGC formed in 30 of 40 (75%) cultures from women with BC, but only in 7 of 40 (17.5%, 0.001 <P<0.01) healthy age-matched controls with no FH of BC. MGC were seen in 14 of 20 (70%) of cultures from sisters (2 of 5) and daughters (12 of 15) of women with BC and a FH (0.001 <P.0.01 compared with controls). These data suggest that the propensity to form MGC under these culture conditions may antedate the development of BC. Further investigation of this phenomenon as a possible marker of risk is warranted. An important part of the successful production of mousemouse hybridomas, has been the ready supply of stimulated B lymphocytes. In the human system it is necessary to stimulate B lymphocytes in vitro prior to fusion. This has been attempted using the mitogens phytohemagglutinin (PHA), as T cell mitogen, pokeweek mitogen (PWM), a T/B cell mitogen, and tetanus toxoid, as a means of B cell activation. Human peripheral lymphocytes were isolated from healthy volunteers. The total number of immunoglobulin (Ig) secreting cells and those specific for tetanus toxoid was assessed by the use of a filter plaque assay. In order to detect activated B cells within the mixed lymphocyte population, a flow cytometric technique simultaneously measuring DNA content and cell surface markers was adopted. Following mitogen stimulation the DNA profiles showed an increased number of cells in S G2 M phase evident in both B and non-B cell populations. This was optimal after 72 h incubation with 1 pig ml -PHA in 5% human AB serum at 1 x 106 cells ml-1. Stimulation was found to be preferable in terms of fusion frequency and hybridoma production with PHA. The effect of B cell activation on specific Ig production is under continued examination before and after fusion.
Biodistribution of rcin toxin
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Analytical and formulation studies on 1,4-bis(2'-chloroethyl)-1,4-diazabicyclol2. Sci., 68, 1539 Sci., 68, , 1979 . The optimized HPLC conditions consisted of a phenyl column (100mm x 8 mm) with a mobile phase of 0.3 mm sodium naphthalene sulphonate in water, adjusted to pH 1.9 with phosphoric acid. Detection was at 260 nm with the 1,4-bis(2'-chloroethyl)-1, 4, diazabicyclo-[2.2. l]-heptane ion eluting as a negative peak with a capacity factor (K') of 0.33. The injection volume of 0.025 ml gave a lower limit of detection of 0.8 mg ml-1 and calibration curves were linear over the concentration range 4.0 to 20.0 mg ml-1. The coefficient of variation for replicate injections (n = 6) was 5.1 % at 2 mg ml -1 and 4.0% at 10mgml-'. The HPLC method was stability-indicating for NSC262666 with the reported degradation product, N,N'-bis(2'-chloroethyl) -piperazine, having a K' of 0.72. Lyophilized preparations of NSC262666 proved to be both chemically and physically unstable at 50°C and room temperature. Aqueous solutions of NSC262666, sterilized by terminal filtration, were found to be stable at 4°C for greater than 12
months. An 8mgml-P solution of NSC262666 in 5% dextrose exhibited no degradation, at room temperature, over a period of 48 h. NSC262666 was formulated for phase I clinical trial as a 50mgml-1 aqueous solution. The 2-CH3 compound is a potent TS inhibitor as well as very cytotoxic and water soluble, properties that make this a very interesting compound for further study. The TS inhibitor, CB3717, was withdrawn from clinical study because of unpredictable liver and kidney toxicities. As the kidney toxicity, at least, was attributable to the poor water solubility of CB3717, 2-desamino CB3717 was synthe- High levels of bile acid secretion have been associated with individual susceptibility to colon cancer. The rate limiting step for bile acid synthesis has long been accepted to be that catalyzed by cholesterol 7a hydroxylase. This minor species of cytochrome P-450 has been shown to be unique through substrate specificity studies and is not readily inducible by phenobarbital or 3-methylcholanthrene. We panying abstracts). The two best TS inhibitors made were the 2-OCH3 and 2-CH3-substituted compounds which were only 1.4 and 2-fold less active than CB3717 (Ki =4 nM). The 2-CH3 analogue was notably the most cytotoxic compound (IC0 =0.085 uM; 2-OCH3IC,=1.9 1iM) although the activity of both could be prevented by co-incubation with thymidine suggesting that TS is their sole locus of action. Using a whole cell TS assay we demonstrated that the 2-CH3 analogue (_0.5 1iM for 4h) caused prolonged inhibition of TS after resuspension of cells in drug-free medium. This is assumed to be due to the formation of polyglutamate metabolites that cannot be effluxed from the cell. Indeed the 2-CH3 analogue has substrate activity for folylpoylglutamate synthetase (FPGS) (Km=60,uM) similar to that of CB3717 (Km=40 yM) where polyglutamation in L1210 cells has been conclusively demonstrated. In contrast the 2-OCH3 analogue could not continue to inhibit TS after the removal of extracellular drug (100,uM for 4h) and this correlates with poorer FPGS substrate activity (Km= 193 , M) although slower transport into the cell may be an additional factor. Synthesis of synthetic polyglutamates of the 2-CH3 compound has shown that they are substantially better inhibitors of TS (-100-fold) than the monoglutamate form (similar to that found with CB3717 polyglutamates). Intracellular metabolism to polyglutamates is an important determinant of cytotoxicity and all 2-desamino-2-substituted CB3717 analogues so far tested for FPGS substrate activity show activity that correlates well with cytotoxicity. Indeed polyglutamation seems to represent an essential activation step for many of the weaker TS inhibitors. For example 2-CHR3-5,8-dideazafolate is 112-fold less active than the propargylated compound described above but equally cytotoxic and this may be accounted for by its very good FPGS substrate activity (Km=10M). In the search for a non-nephrotoxic and non-hepatotoxic antifolate thymidylate synthase (TS) inhibitor a series of C2-desamino-C2 one carbon substituted CB3717 analogues have been synthesised. Of these, the C2-CH3 analogue is only 2 fold less potent than CB3717 as a TS inhibitor yet 40 fold more toxic to tumour cells grown in vitro. Ther toxicities of CB3717 and analogues substituted at the C2 position with -H, -CH3, -CH2F and -CH2OH have been compared in mice. CB3717 (100 mg kg-1 i.v.) caused both liver (raised alanine transaminase) and kidney (raised urea and creatinine) damage whilst the analogues induced no toxicity. This may be due to their greatly enhanced (>100 x ) solubility at physiological pH. The pharmacokinetics of CB3717 (100mgkg-1 i.v.) and the C2-H and C2-CH3 analogues (500mgkg-1) were compared in mice with sample analysis by HPLC. CB3717 was cleared slowly from the plasma (0.31 h-1 kg-1t1/2 90 min) whilst the analogues were cleared rapidly (C2-H 4.81 -1hkg-1 t1/2 21 min, C2-CH3
2.51 h-1 kg-t'12 16min). For all three compounds 0-24h urinary excretion accounted for 20-30% of the dose, however, faecal elimination of the two analogues was more extensive (50% dose 0-24h) than with CB3717 itself (20% dose 0-24 h). The enhanced plasma clearance and faecal excretion of the analogues was probably a result of their lack of hepatotoxicity. Pharmacokinetics have also been studied non-invasively in mice (500 mg kg-1 i.v.) and rats (100mgkg-1 i.v.) by in vivo 19F-NMR spectroscopy using the 2-CH3-6'-CH3 CB3717 analogue. In both species compound could be detected in the upper abdomen shortly after injection (rats <2 min). As 70-80% of the dose was excreted in the bile within 1 h the signal was presumably due to compound undergoing biliary elimination. These studies have identified C2-desamino-C2 substituted analogues of CB3717 as non-hepatotoxic and non-nephrotoxic antifolates and have established further the viability of 19F-NMR in pharmacokinetic monitoring. The evaluation of the efficacy of TS inhibitors in murine tumour systems is complicated by the high levels of circulating thymidine in the host mice. PLAP appears to be of little value as a serological marker used alone to monitor OCA (Fisken et al., Clin. Sci., 73, (suppl. 17), 9, 1987) . However its additive value in combined assays has been alluded to by other workers. We have assessed the value of sequential assays for CA125 and PLAP in the management of clinically advanced OCA. Both CA125 and PLAP activity (PLAP-A) and concentration (PLAP-C) were measured in 397 samples over time from 87 patients . Active disease was present at the time of sampling in 261 instances. CA125 detected 73% (190/261) of the true positive (TP) samples with only 6 false positive (FP). When the remaining 71 samples were assayed by PLAP-A 40 were TP. Of the 31 'double negatives' 13 were TP for PLAP-C. Thus sensitivity apparently increases from 73% to 93% using all 3 assays. However, analysis of all 397 samples indicated significant numbers of FP with PLAP-A and PLAP-C. The predictive power of a positive result actually falls from 97% with CA125 alone to 76% by adding in PLAP assays. Similarly the FN rate for PLAP is high therefore predictive power of a negative result rose only from 65 to 76%. These data indicate that the PLAP assay is detrimental to the resolving power of CA125 alone despite attractive figures for apparent sensitivity. Modified nucleosides such as PSU have been proposed as markers for several common solid tumours (Speer et al., Cancer, 44, 2120 Cancer, 44, , 1979 but its value as a marker in breast cancer has not been extensively investigated. Urinary PSU was measured by HPLC after preliminary isolation on Affigel columns (Kuo et al., J. Chromatogr., 145, 383, 1978) . We have confirmed that measurement of a random urine sample is comparable with a 24 h urine collection, if the PSU is expressed in relation to creatinine concentration, i.e. nmol PSU umol-I Cr. Our laboratory normal range was 12.6-26.4 units. PSU levels do not display any circadian rhythm or alter through the menstrual cycle. To test the efficiency of PSU as a preclinical cancer marker, urinary levels were measured in 24 women who subsequently developed breast cancer each with 10 matched controls (Bulbrook et al., Breast Cancer Res. & Treat., 7 (Suppl.), 5, 1986). The urinary PSU levels in the 'pre-cancer cases' were not significantly different from the controls. We measured urinary PSU levels in patients before and after primary surgery for breast cancer and compared them with patients undergoing other major surgery. PSU levels were frequently not elevated above normal initially and did not fall after treatment. Also, PSUs were measured in 30 patients receiving post-operative radiotherapy for breast cancer; 43% had elevated urinary PSU (30-71 units). There was a non-significant tendency for higher levels with increased primary tumour size. PSU levels did not correlate with disease state as assessed by metastatic survey:
In other malignancies it has been reported that elevated excretion of PSU is a negative prognostic factor correlating with shorter survival time (Rasmuson et al., Bull. Mol. Biol. Med., 10, 143, 1985) . The importance of markedly increased PSU in individual breast cancer patients can only be determined by continued 'follow-up' of these subjects.
has a unique and extensive pattern of metabolism involving glucuronidation. There is little work relating the pharmacokinetics and metabolism of cytotoxic drugs to response or toxicity for a number of reasons: inconvenience of carrying out full pharmacokinetic studies; cost; problems with drug assay; insufficient patient numbers; unresponsive disease/ ineffective drugs. A prospective randomised trial in advanced breast cancer comparing epirubicin at 2 doses (50 mgm 2 and 100mg m-2) is underway locally. A single plasma sample was taken in 43 patients 30 min following bolus administration of epirubicin. Using a sensitive and specific HPLC assay it was possible to detect the parent compound and 5 metabolites. Nineteen patients are assessable for response (CR+PR) at 27 weeks following initiation of therapy; high dose, 6/9 response; low dose, 4/10 responses. Comparing high dose and low dose groups, there was no significant difference in parent drug concentrations (82 ng ml-1 vs. 67 ng ml -1) or in metabolite levels (total fluorescent compounds 241 ng ml-1 vs. 203 ng ml-1). There were no correlations between drug levels and responses although the single patient with a CR had a high epirubicinol level (more than 3 stand deviations from the mean). 9 patients have had multiple samples taken following identical doses and there was wide intra-individual variation in drug and metabolite levels from course to course.
Large patient numbers will need to be recruited to reveal any correlation between plasma drug concentration and response due to intra and inter individual variation in drug handling. The anti-breast carcinoma monoclonal antibody, NCRC-11, defines a family of high molecular weight glycoproteins (>400kD) associated with malignant cells and specialised normal secretory epithelia. These components have also been found to be elevated in the circulation of breast cancer patients.
Pooled serum from primary breast carcinoma patients was fractionated by affinity chromatography using Sepharoselinked NRC-11 antibodies. Non-specifically bound material, in particular human IgG and IgM, was separated from NCRC-l1 defined antigen by gel filtration using Sephacryl S-300 chromatography after reduction of the sample with dithiothreitol, DTT (antigenic material being unaffected by DTT). Similar fractionation of a pool of serum from normal age and sex matched donors failed to produce any detectable NCRC-11 defined antigen.
The purified NCRC-11 defined antigen from patients' serum was characterised by SDS PAGE and Western blotting, by epitope mapping studies using a panel of reactive monoclonal antibodies and by enzyme digestion and lectin binding tests. The characteristics of this antigen from patients' serum were comparable to those of antigen preparations from primary tumour tissue. Events which occur early in the reproductive life (e.g. early menarche) of the female are associated with risk of breast cancer (BC) in later life. Korenman (Cancer., 46, 874, 1980) proposed that luteal phase progesterone (P) was antiproliferative and that the early onset of anovular cycles led to the unapposed stimulation of epithelial cells and thus increased risk. We have tested the hypothesis that P is antiproliferative by relating the labelling (LI), mitotic (MI) and apoptotic (Al) indices of histologically normal breast tissue to the day of the menstrual cycle, age and serum P values in 122 women undergoing opertions to remove fibroadenomas (n =116) or reduction mammoplasty (n = 6). Thirty-three were taking the oral contraceptive pill. Thin tissue slices were incubated with tritiated thymidine (37 kBqnml-1) and processed for autoradiography. More than 1,000 cells were counted to determine the LI, MI and AI for each sample. The LI ranged from 0-11.5% was cyclic with a maximum on day 20.8 and declined with age (0.7% per decade). The MI ranged from 0-0.6% with a maximum on day 21.5 and declined at a rate of 0.05% per decade. The AI was unrelated to the menstrual cycle but significantly declined with age. There was no significant effect of the contraceptive pill on the proliferative indices. Maximum LI was associated with high serum P values. These data indicate that the maximum proliferative rate of mammary epithelium occurs in the luteal phase of the cycle and suggests that P is not antiproliferative. They support the studies of Henderson et al. (Cancer, 56, 1206 , 1985 which show that the early onset of regular (and hence ovular) cycles are related to risk of BC. The calcium transport blocker, verapamil (VRP) is an effective modifier of resistance to adriamycin (ADM) and vincristine (VCR) in many multi-drug resistant (MDR) cell lines. In order to study the mechanism of such modification we have derived a VRP resistant subline (EMT6/VRP) of the mouse tumour cell line EMT6. Subline EMT6/VRP is 3.9 fold resistant to VRP (ID50 = 94 ig ml-1 cf. 24 Mg ml -1) but does not show cross-resistance to ADM or VCR. Similarly an MDR subline (EMT6/AR1.0) is resistant to ADM and VCR but not to VRP. Whereas EMT6/ARl.0 hyperexpresses the mRNA for P-glycoprotein, EMT6/VRP does not. The accumulation of 3H-VRP by EMT6/VRP is increased compared with the parent line whereas that by EMT6/ARl.0 is slightly decreased. The accumulation of 3H daunomycin on the other hand is increased 2 to 3 fold compared with the parent line in EMT6/VRP but is only 22% of the parent in EMT6/AR1.0. The sensitivity of all 3 cell lines to ADM is enhanced by the addition of 6.6 MM VRP (parent= 11.0 fold; EMT6/ARl .0 = 8.8 fold; EMT6/VRP = 6.1 fold).
We are currently studying the cross-resistance of EMT6/ VRP to other resistance modifiers.
It appears that resistance to VRP occurs via a different mechanism to classical MDR and that VRP-resistance leads to a partial reduction in the ability of VRP to sensitise cells to ADM. We have determined the chemosensitivity of this cell line to adriamycin by an assay based on the reduction of a tetrazolium dye, MTT. The ID50 for a 24 h exposure to adriamycin was 3.0 x 10-8 M. However, exposure to adriamycin for 72 h decreased the ID50 by -50 fold to 6.0 xO10 M.
The calcium antagonist verapamil has been shown to increase the sensitivity of some cell lines to adriamycin. However, in this cell line exposure for 72 h to adriamycin in the presence of verapamil (6.6 MM) decreased the sensitivity by about 3 fold. In contrast, incubation of cells for 24 h in the presence of verapamil (6.6 MM) alone prior to a 24 h exposure to adriamycin and verapamil increased the sensitivity by -3 fold. Clearly this adherent SCLC cell line will be of value in our studies to elucidate the role of verapamil in the treatment of SCLC. Departments of 'Therapeutics and Pharmacology, 2Anatomy, and 3Biochemistry, The Queen's University of Belfast, UK.
We have maintained the ZR-751 human breast cancer cell line in the continual presence of tamoxifen (2-4MM), for 2 years. After 6 months oestrogen receptor (ER), expression by tamoxifen exposed cells (designated ZR-75-9al), had fallen from 225+19 to 56+12fmolmg-1 protein as determined using a whole cell binding assay. After a further 18 months routine culture in the presence of 4MM tamoxifen both ER and progesterone (PGR), receptors had fallen to undetectable levels and this was accompanied by a marked reduction in sensitivity to antioestrogens.
Under phase contrast microscopy ZR-75-9al cells appear smaller than the parent line, tending to grow in 'islands' containing mounds of cells. Transmission electron microscopy revealed a marked reduction in intra-cellular lipid. Tonofilaments and desmosomes have not been observed. 9al cells maintained in medium devoid of tamoxifen or oestrogenic activity (phenol red free medium containing dextran charcoal stripped serum), remained ER and PGR negative and tamoxifen resistant for at least 3 months. In contrast, cells transferred to drug free 'complete' medium became ER and PGR positive and tamoxifen sensitive within one month.
We conclude that prolonged exposure of ZR-75-1 cells to tamoxifen does not result in the selective loss of ER positive cells but to a suppression of ER expression with consequent loss of tamoxifen sensitivity. Our data further suggest that recovery of ER and PGR levels only occurs in the presence of oestrogenic stimuli. Current evidence suggests that of the lesions induced in DNA by ionising radiation, double-strand breaks (dsb) are the most closely related to cell death. In support of this, recent data suggest that differences in radiosensitivity in rodent cell lines are related to differences in dsb induction (Radford, Int. J. Radiat. Biol., 49, 611, 1986) .
We have investigated the induction of dsb in 3 human lung carcinoma lines and 3 human cervical carcinoma lines, of varying sensitivity. Irradiations were performed using 60Co y-rays at a dose rate of 1-1.5 Gy min-and cell survival measured using monolayer and soft agar clonogenic assays.
Dsb were measured following irradiation at ice-bath temperature using the neutral filter elution technique (pH 9.6). No significant differences were seen in dsb induction up to 45 Gy in tumour cell lines with Do 0.88-1.8 Gy. We conclude that within the limits of the commonly used neutral elution assay, induced dsb may not correlate directly with cell kill in human tumour lines. While this does not invalidate the idea that dsb may be the lethal lesion following exposure to ionising radiation, it does suggest that the processing of these lesions following induction may be the critical factor in determining radiosensitivity. Changes in the cellular levels of glutathione transferase (GST) enzymes appear to play an important role in preneoplasia and in the resistance of tumour cells to cytotoxic drugs. It is therefore important to understand the factors which regulate the levels of these compounds within cells. To this end we are studying GST regulation by both exogenous and endogenous compounds. Treatment of rats with phenobarbital (PB) and 3-methylcholanthrene (3-MC) leads to significant induction of hepatic Ya/Yc and Yb mRNA levels. As these compounds also induce cytochrome P-450, a multienzyme system involved in foreign compound metabolism, we have looked at the effect of a wide range of cytochrome P-450 inducing agents on GST mRNA levels in rat liver. The compounds used and their relative effect are given below: Purified rat and human liver GSH transferases from the soluble supernatant fraction have activity towards DNA peroxidized aerobically by ionizing radiation. GSH transferases 5-5, 3-3 and 4-4 are the most active in the rat (500, 35 and 20 nmolmin-l mg-' respectively) and GSH transferases , and 7r the most active in man (80 and 10 nmol min-mg-I protein respectively). In rat liver nuclei two GSH transferase fractions were obtained, one extractable with saline/EDTA ('free') and the other with 8.5 M urea ('bound'). The 'free' fraction contained GSH transferase subunits 1 (40%); 2 (25%); 3 (5%); 4 (5%) and a subunit similar to 5 and referred to as 5* (25%). The 'bound' fraction contained principally subunit 5* (95%) and a small amount of subunit 6. A Se-dependent GSH peroxidase fraction from rat liver was also active towards peroxidized DNA, but since it accounts for only 20% of the free GSH peroxidase activity in the nucleus, GSH transferases may be more important. The results implicate a role for GSH peroxidases in DNA repair. (Carmichael et al., Cancer Res., 46, 4916, 1986) and for adriamycin (ADR) + IFN against a human breast tumour (Balkwill et al., Cancer Res., 44, 904, 1984 Cancer, 56, 519, 1987) . SB induced both these markers in these cell lines (Table below) after 4 days exposure at cytostatic doses (>3mM). Alkaline phosphatase was also induced in these cells at these doses (Table) . These phenotypes were determined by (immuno-) histochemical staining. MoAbs (defined as Cluster 1) active against SCLC which show strong neural activity (R.L. Souhami et al., Lancet, 8554, 325, 1987) . Other members of Cluster 1 were not induced in these cell lines after exposure to SB. The effect of SB on other possible differentiation markers in these cell lines is currently being examined. The differential staining of cells with a vital dye can be carried out on fixed cells (Yip & Auersperg, In Vitro, 7, 323, 1972) . This finding along with the publication of the 'DiSc' assay for determining in vitro chemosensitivity of haematological malignancies (Bird et al, Leukemia Res., 10, 445, 1986 ) caused us to consider the possible use of an alcian blue based dye exclusion assay on previously fixed cells.
Following treatment cells (Molt4 and Daudi) were cultured for 4 days when they were fixed in glutaraldehyde in phosphate buffer. They were left in iced water for 1 h and subsequently at 4°C. The samples were stained with alcian blue including duck red cells (internal standard) and slides prepared using a cytospin centrifuge. We found that with cell lines counterstaining was unnecessary and slides could be rapidly prepared by dehydrating in ethanol followed by clearing in xylene and mounting with Canada balsam. Where counterstaining was required we used Giemsa followed by the above procedure.
Using two cell lines we have obtained dose response curves following radiation and drug (Adriamycin and AraC) exposure in our dye exclusion assay, a soft agar clonogenic and MTT assay. We consider this ability to fix cells for examination/processing at a later date to be of general use. It is also preferable to deal with fixed samples where possible. For The uptake of a number of chemotherapeutic agents and their cytotoxicity are enhanced by Tween80 in vitro and in vivo. Added to ThioTEPA, the non-ionic detergent significantly reduced the colony-forming ability of a human bladder cancer cell line (Parris et al., Urol Res., 15, 17, 1987) . Therefore, this combination might be more effective than drug alone for intravesical chemotherapy of superficial bladder cancer, although Tween80 could increase the systemic absorption of ThioTEPA and so potentiate its myelosuppressive effects. A pharmacokinetic study using a randomised cross-over design was performed in which 8 patients with multiple recurrent stage pTa or pTI disease were given ThioTEPA (30mg) in distilled water or in 10% (v/v) Tween80 (30ml) for 2h, followed 3 months later by the alternative treatment. Large variation occurred in the proportion of ThioTEPA absorbed (20-78%), but the rate of absorption was not affected by Tween 80. We have examined 55 tumour bearing tissues taken from the head and neck regions as frozen sections. We employed 9-aminoacridine as a fluorescent probe for cells possessing the tumour associated protease guanidinobenzoatase. We observed that most of the cells within the tumour masses in these sections did not bind 9-aminoacridine and therefore possessed inhibited enzyme which was subsequently exposed by displacement of the inhibitor. We noted that the cells at the advancing edge of the tumour masses and individual tumour cells in the stroma bound 9-aminoacridine and fluoresced. Guanidinobenzoatase is known to degrade fibronectin and we believe that those cells possessing uninhibited guanidinobenzoatase in vivo are capable of migration and tissue invasion. We observed that guanidinobenzoatase in solution and on the surface of these fluorescent tumour cells was inhibited by 10 -6 M bis-(carbobenzoxy-arginine)-rhodamine in an irreversible manner. This synthetic inhibitor had no action on trypsin or cell-bound guanidinobenzoatase which was already complexed with the normal inhibitor in these frozen sections. We conclude that the activity of tumour cell guanidinobenzoatase is regulated in vivo by the naturally occurring inhibitors. Only those cells at the advancing edge of the tumour mass possessed active enzyme and this could be selectively inhibited by a synthetic arginine derivative. There is debate as to whether peri-operative blood transfusion is associated with a poorer prognosis in patients undergoing tumour resection. The results of retrospective clinical studies are conflicting and difficult to interpret. Preliminary experiments in a mouse tumour model indicated that spontaneous metastases from a subcutaneous primary were augmented when the animals were transfused with allogeneic blood 14 days before tumour inoculation. Further studies have now investigated the effect of both the timing of the transfusion and the strain of the donor blood.
Groups of C3H (H2k) mice were transfused with 0.25 ml of C57/B16 (H2b) blood at days -14, -7, 0 and +7 in relation to an inoculum of UV-2237 fibrosarcoma cells at day 0. Control groups were transfused with syngeneic blood at each time point. Animals were all killed at day + 21 and those transfused with allogeneic blood on days -14, -7 and + 7 showed a significant increase in the number of pulmonary tumour deposits compared with controls. This effect was dependent on the dose of tumour inoculated, being most marked when the injected dose was near the minimum dose needed for tumour growth (MTD).
In further experiments, groups of mice were inoculated with UV-2237 cells and on day + 7 were transfused with blood from donors which varied both at the major and/or the minor histocompatibility antigen loci. At day + 21 the mice were killed to assess lung colonisation and the results showed that the augmentation of tumour deposits by blood transfusion was dependent on the donor strain and suggested that differences in both major and minor histocompatibility antigens may be involved.
Use of a monoclonal antibody-mediated haemadsorption method to identify tumour cell colonies in mixed cultures M.J. Embleton, K. Affleck & A. Capuano use of such conjugates to quantitate the rate of uptake is difficult due to fluorescence quenching by various factors. Rate of uptake was therefore quantitated using 1251-labelled antibody.
After binding labelled antibody to cells at saturating levels, endocytosis was allowed to proceed for various times at 37°C. Bound non-endocytosed material was removed from cells by digestion with papain on ice, followed by centrifugation. The percent endocytosis compared to material originally bound at time zero was then calculated by the following equation:
Percent endocytosis = P,-St x PO/SO x 100/PO + SO where P = cpm in pellet, S = cpm in supernatant, subscript 0 = time 0 and subscript t = time t. This equation corrects for bound material not completely digested from the cell surface.
Use of this assay to quantitative uptake of 1251-791T/36 antibody on 791T cells showed 30% uptake after 4 h. The specificity of uptake was demonstrated by washing cells prior to endocytosis, but true rates of endocytosis were given by incubation with antibody throughout the assay. The latter method showed that uptake was linear for a minimum of 4 h, strongly indicative of a pinocytic rather than a receptormediated endocytic process.
Cancer Research Campaign Laboratories, University of Nottingham, Nottingham NG72RD, UK.
A method involving adherence of monoclonal antibody (MoAb)-coated sheep red blood cells (SRBC) was developed to facilitate the identification of adherent colonies growing in cultures of mixed tumour cells, established for the purpose of studying cellular interactions. Anti-tumour MoAbs were purified by affinity chromatography and adjusted to 1 mg ml-I in 0.9% w/v sodium chloride without buffers. A 1% w/v solution of chromic chloride was adjusted to pH 5.0 and left to 'age' for at least 3 weeks. SRBC were washed twice in 0.9% NaCl and spun down, and appropriate volumes of cell pellet were added to an equal volume of antibody, followed immediately by addition of CrCl3 while agitated on a vortex mixer. The SRBC were left for 10min at 20°C and washed twice in phosphate-buffered saline (pH 7.2) before resuspension in Eagle's MEM +10% calf serum. Mixed cultures containing tumour cell colonies were drained of medium and the MoAb-coated SRBC were added, followed by 20min incubation at 20°C. The cultures were then rinsed free of unattached SRBC, fixed in methanol, and stained with Leishman's stain.
Using tumour cell lines and MoAbs of known reactivity, it was established that MoAb-coated SRBC adsorbed strongly to colonies of cells bearing the antigen recognised by the MoAb. SRBC treated with saline or a non-cross-reactive MoAb did not bind to cell colonies, although the sensitivity of the assay was such that weak cross-reactions gave a positive result. By careful matching of MoAbs to the cells used, this method provides a useful means of identifying colonies of cells with similar morphology in mixed cultures. When the nuclei of human lymphocytes are challenged with 2 M NaCl a histone-free-DNA-protein (HF-DNA) complex is released (Harris et al., Int. J. Radiat. Biol., 47, 689, 1985; George et al., Br. J. Cancer, 55, 141, 1987) . The sedimentation distance of the HF-DNA complex in a linear sucrose gradient (pH 8.0) is less when immediately isolated from in vitro irradiated cells than that when isolated from unirradiated cells. Typically, there is a non-linear dose response in the sedimentation behaviour. At low doses, if irradiated cells are incubated at 37°C the sedimentation behaviour approaches that of unirradiated cells ('repair') -generally, repair is complete after an incubation of 1 h at 37°C.
The repair of irradiated lymphocytes derived from 'healthy' control donors was similar to that of lymphocytes derived from patients with carcinoma of the uterine cervix (blood was taken when the patient presented at the first clinic for radiotherapy). Most donors demonstrated complete repair following an incubation of 1 h at 37°C. However, 2/28 (7%) controls and 2/25 (8%) patients were repair. deficient showing a less than 30% repair following incubation. In addition, the repair of irradiated lymphocytes derived from patients treated by radiotherapy 2 to 5 years previously for carcinoma of the uterine cervix has been examined. Of those now attending with 'bowel complications' attributed to radiotherapy 7/16 (44%) showed a less than 30% repair. In contrast, all those (11/11) described as 'well and complication-free' showed good repair, that is greater than 80% repair on incubation.
The activation of CB1954 (2,4-dinitro-5-aziridinyl benzamide) Confluent (stationary phase) human foetal lung cells recover from damage induced by either radiation or cis-platin but with different kinetics, that from radiation being maximal after 2 days, irrespective of the initial dose, while that from cis-platin was continuous for up to 10 days. At late times after treatment of cells with a combination of the two agents the cells exhibited a toxic response equal to the sum of that produced by either agent alone. Irradiation of exponentially growing human foetal lung cells before, during or following a 1 h pulse treatment with cis-platin also resulted in a toxic effect equal to the sum of that produced by either agent alone. CBA nude mice implanted with a human melanoma were either irradiated (12.5 Gy), injected with carboplatin (100mgkg-1) or injected with carboplatin 45min before irradiation. The effect of these treatments on the survival of tumour cells was determined by their colony-forming ability in vitro I h later. The combination of carboplatin and radiation produced an effect on cell survival equal to the sum of the two separate treatments. Thus radiation and platinum compounds act independently on both normal and tumour human cells, a finding which suggests a common mechanism of action and accounts for the beneficial therapeutic effects obtained when they are used in combination. The tumour-associated antigens CEA, CA19-9 and CAS0 defined by monoclonal antibodies have been raised against human colorectal adenocarcinoma cell lines. The aim of this study was to assess their combined use to identify patients with oesophagogastric carcinoma.
An immunoradiometric assay was used for the detection of CEA and CA 19-9 and the Delfia system was used for CA50. Serum was collected from 50 control patients (of whom 23 had benign upper gastrointestinal disease and 27 were normal subjects) and 23 patients with oesophagogastric carcinoma. The 'cut-off' discriminant levels for CEA, CA 19-9 and CA50 were 5.4 ng ml 1, 33.2 U ml 1 and 35.5 U mlrespectively.
The combination of antibodies was positive in only 1 (2%) of the control group and 16 of 23 (70%) with oesophagogastric carcinoma (Table) . for SCLC. In this group median FpA was normal, at 3.3pmolml-1, and although median B,B was modestly elevated (7.1 pmol ml -1), the median FpA/Bfl ratio was normal (0.41). The difference in thrombin activity and also in the ratio of thrombin generation to fibrinolysis between these two groups was significant (P <0.001, Mann-Whitney Utest). This is the first study in cancer patients to show a relationship between increased thrombin activity and a lack of response to chemotherapy. Volume densities of filaments were similar in carcinogentreated epithelia when compared with normal epithelia, but average cell volumes of filaments in each compartment increased progressively following carcinogen treatment. We conclude that carcinogen-induced preneoplastic lesions are accompanied by increased synthesis of cytokeratins, which may be related to the premature abnormal keratinisation so frequently seen in dysplastic epithelium.
